Cynthia Feldmann Sells 3,098 Shares of STERIS (NYSE:STE) Stock

STERIS plc (NYSE:STE) Director Cynthia Feldmann sold 3,098 shares of the business’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $237.21, for a total transaction of $734,876.58. Following the transaction, the director owned 705 shares of the company’s stock, valued at approximately $167,233.05. The trade was a 81.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

STERIS Stock Down 3.4%

STERIS stock opened at $230.49 on Friday. STERIS plc has a 1-year low of $204.90 and a 1-year high of $269.44. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.48 and a quick ratio of 1.75. The stock has a market cap of $22.60 billion, a PE ratio of 32.15 and a beta of 1.05. The stock’s fifty day moving average is $254.37 and its two-hundred day moving average is $251.54.

STERIS (NYSE:STE) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.STERIS’s revenue for the quarter was up 9.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, sell-side analysts expect that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 19th. Investors of record on Tuesday, February 17th will be paid a dividend of $0.63 per share. The ex-dividend date is Tuesday, February 17th. This represents a $2.52 annualized dividend and a yield of 1.1%. STERIS’s payout ratio is presently 35.15%.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $275.20.

Institutional Trading of STERIS

Institutional investors and hedge funds have recently made changes to their positions in the company. Trust Co. of Vermont grew its stake in STERIS by 30.2% during the 4th quarter. Trust Co. of Vermont now owns 164 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 38 shares during the last quarter. Bailard Inc. lifted its stake in STERIS by 3.5% in the fourth quarter. Bailard Inc. now owns 1,118 shares of the medical equipment provider’s stock valued at $283,000 after buying an additional 38 shares during the last quarter. Magnolia Capital Advisors LLC lifted its stake in STERIS by 1.2% in the third quarter. Magnolia Capital Advisors LLC now owns 3,588 shares of the medical equipment provider’s stock valued at $888,000 after buying an additional 41 shares during the last quarter. Colonial Trust Co SC boosted its holdings in shares of STERIS by 0.3% in the third quarter. Colonial Trust Co SC now owns 12,329 shares of the medical equipment provider’s stock valued at $3,051,000 after acquiring an additional 42 shares during the period. Finally, Allworth Financial LP boosted its holdings in shares of STERIS by 7.3% in the second quarter. Allworth Financial LP now owns 661 shares of the medical equipment provider’s stock valued at $159,000 after acquiring an additional 45 shares during the period. 94.69% of the stock is owned by hedge funds and other institutional investors.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.